↓ Skip to main content

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States

Overview of attention for article published in Frontiers in immunology, September 2023
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (64th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
1 X user
patent
1 patent

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
8 Mendeley